Xingbei Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xingbei Dong has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Junwei Zhang
Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, China (J. Zhang, Y.Y.).
2 shared publications- Junyan Qian
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
2 shared publications - Mengtao Li
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
2 shared publications - Qian Wang
Department of Rheumatology Peking Union Medical College Hospital Beijing China
2 shared publications Chen Wang
State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (X.J., H.H., Y.G., Y.X., Y.H., H.Z., W.S., P.Y., C.W.).
1 shared publicationDan Chen
Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University
1 shared publication
Latest Publications
- 23 October 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (10)
Pathogenic B-T Cell Axis Driven by BAFF Induces Endothelial Apoptosis in SLE-PAH
BACKGROUND: Pulmonary arterial hypertension (PAH) is a fatal complication of systemic lupus erythematosus (SLE), yet the mechanisms linking autoimmune dysregulation to progressive pulmonary vascular remodeling are poorly defined, leading to inadequate therapies. This study investigated BAFF (B-cell activating factor), a key cytokine in SLE, as a potential driver of SLE-PAH pathogenesis. METHODS: BAFF expression was assessed in patients with SLE-PAH and animal models. Humanized BAFF-transgenic mice were generated to investigate the effects of BAFF elevation on serological, hemodynamic, and histological parameters of SLE and PAH. Single-cell RNA sequencing, flow cytometry, histological analyses, and cell-based experiments were performed to elucidate cellular and molecular mechanisms. The therapeutic efficacy of the BAFF-neutralizing antibody Belimumab was tested in 2 distinct SLE-PAH animal models. RESULTS: BAFF was significantly upregulated in both SLE-PAH patient cohorts and animal models. Humanized BAFF-transgenic mice exhibited systemic B-cell hyperactivation and pulmonary infiltration and spontaneously developed hallmark features of both SLE and PAH. Single-cell transcriptomic analysis of lung tissues revealed that BAFF overexpression drove the increase of a novel, disease-specific S 100a6 + mature B-cell subset, which orchestrated a pathogenic immune cascade by activating a cytotoxic Gzmk + CD8 + T-cell population via MHC-I (major histocompatibility complex class I)-mediated antigen presentation and CD80-CD28 costimulation. This B-T cell crosstalk triggered apoptosis of a susceptible endothelial cell subpopulation through Fas/Fas ligand signaling, ultimately culminating in pulmonary vascular remodeling. The BAFF-neutralizing antibody Belimumab effectively ameliorated both autoimmune and cardiopulmonary manifestations in 2 distinct SLE-PAH animal models, while improving survival. CONCLUSIONS: These findings establish BAFF as a key mediator in SLE-PAH, driving a previously unrecognized pathogenic immune axis connecting dysregulated B cells to T-cell-mediated endothelial injury. BAFF inhibition may represent a therapeutic strategy for SLE-PAH.
- 23 October 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (10)
Pathogenic B-T Cell Axis Driven by BAFF Induces Endothelial Apoptosis in SLE-PAH
BACKGROUND: Pulmonary arterial hypertension (PAH) is a fatal complication of systemic lupus erythematosus (SLE), yet the mechanisms linking autoimmune dysregulation to progressive pulmonary vascular remodeling are poorly defined, leading to inadequate therapies. This study investigated BAFF (B-cell activating factor), a key cytokine in SLE, as a potential driver of SLE-PAH pathogenesis. METHODS: BAFF expression was assessed in patients with SLE-PAH and animal models. Humanized BAFF-transgenic mice were generated to investigate the effects of BAFF elevation on serological, hemodynamic, and histological parameters of SLE and PAH. Single-cell RNA sequencing, flow cytometry, histological analyses, and cell-based experiments were performed to elucidate cellular and molecular mechanisms. The therapeutic efficacy of the BAFF-neutralizing antibody Belimumab was tested in 2 distinct SLE-PAH animal models. RESULTS: BAFF was significantly upregulated in both SLE-PAH patient cohorts and animal models. Humanized BAFF-transgenic mice exhibited systemic B-cell hyperactivation and pulmonary infiltration and spontaneously developed hallmark features of both SLE and PAH. Single-cell transcriptomic analysis of lung tissues revealed that BAFF overexpression drove the increase of a novel, disease-specific S 100a6 + mature B-cell subset, which orchestrated a pathogenic immune cascade by activating a cytotoxic Gzmk + CD8 + T-cell population via MHC-I (major histocompatibility complex class I)-mediated antigen presentation and CD80-CD28 costimulation. This B-T cell crosstalk triggered apoptosis of a susceptible endothelial cell subpopulation through Fas/Fas ligand signaling, ultimately culminating in pulmonary vascular remodeling. The BAFF-neutralizing antibody Belimumab effectively ameliorated both autoimmune and cardiopulmonary manifestations in 2 distinct SLE-PAH animal models, while improving survival. CONCLUSIONS: These findings establish BAFF as a key mediator in SLE-PAH, driving a previously unrecognized pathogenic immune axis connecting dysregulated B cells to T-cell-mediated endothelial injury. BAFF inhibition may represent a therapeutic strategy for SLE-PAH.
- Open Access
Improvements and challenges of long-term survival in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: A 10-year multi-center cohort study
Background Prior studies indicated improved survival in systemic sclerosis-associated pulmonary arterial hypertension (PAH) patients, but trends in systemic lupus erythematosus-associated PAH (SLE-PAH) survival remained unclear. Methods Analysing SLE-PAH patients from the nationwide CSTAR-PAH cohort, we divided them into two cohorts: A (2011-2016) and B (2016-2021), based on baseline right heart catheterization dates. We compared clinical characteristics, mortality, and treatment outcomes between these cohorts and with idiopathic PAH (IPAH) patients. Results We enrolled 610 and 104 patients with SLE-PAH and IPAH, respectively. Patients with SLE-PAH were younger, had a higher proportion of low-risk patients, and had a significantly higher 10-year survival rate than those with IPAH (66·6% vs. 44·1%, p < 0·001). Cohort B had a longer 6-min walk distance, lower mean pulmonary arterial pressure and pulmonary vascular resistance, a better-preserved cardiac index, and less right ventricular dilation than cohort A. More patients in cohort B received intensive immunosuppressant- and PAH-targeted therapies. The 5-year survival rate was significantly higher in cohort B (88·1% vs. 77·5%, p = 0·006). Reaching low-risk profile of PAH (hazard ratio [HR] 0·34, 95% confidence interval [CI] 0·15-0·79, p = 0·012) and reaching lupus low-disease-activity state (HR 0·33, 95% CI 0·14-0·82, p = 0·016) were independent predictors of survival. The rate of achieving low-risk profile for PAH was considerably higher in patients initially treated with intensive immunosuppressive and dual-PAH-targeted therapies. Conclusions Over the last decade in China, the clinical characteristics of patients with SLE-PAH have evolved and survival has improved. Early PAH detection and dual treatment-to-target strategies for both PAH and SLE have contributed to this improvement in survival. What is new? This is the largest multi-center prospective cohort study of SLE-PAH with the longest follow-up period describing changes in the characteristics, treatment regimen, and long-term survival of patients with SLE-PAH. Our study showed that the 5-year survival rate of patients with SLE-PAH has increased remarkably from 77·5% to 88·1% during the last decade. Our study demonstrated that reaching lupus low-disease-activity state is independently associated with reduced mortality. Significantly more patients reached low-risk profile of PAH during follow-up with initiation of intensive immunosuppressive therapy. What are the clinical implications? Our study emphasised on the importance of achieving dual treatment goals for both SLE and PAH (dual treat-to-target strategy). Earlier detection of PAH in patients with SLE, timely initiation of intensive immunosuppressive therapy, and upfront combination PAH-targeted therapy benefit patients in achieving PAH low-risk profile.
Open AccessImprovements and challenges of long-term survival in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: A 10-year multi-center cohort study
Background Prior studies indicated improved survival in systemic sclerosis-associated pulmonary arterial hypertension (PAH) patients, but trends in systemic lupus erythematosus-associated PAH (SLE-PAH) survival remained unclear. Methods Analysing SLE-PAH patients from the nationwide CSTAR-PAH cohort, we divided them into two cohorts: A (2011-2016) and B (2016-2021), based on baseline right heart catheterization dates. We compared clinical characteristics, mortality, and treatment outcomes between these cohorts and with idiopathic PAH (IPAH) patients. Results We enrolled 610 and 104 patients with SLE-PAH and IPAH, respectively. Patients with SLE-PAH were younger, had a higher proportion of low-risk patients, and had a significantly higher 10-year survival rate than those with IPAH (66·6% vs. 44·1%, p < 0·001). Cohort B had a longer 6-min walk distance, lower mean pulmonary arterial pressure and pulmonary vascular resistance, a better-preserved cardiac index, and less right ventricular dilation than cohort A. More patients in cohort B received intensive immunosuppressant- and PAH-targeted therapies. The 5-year survival rate was significantly higher in cohort B (88·1% vs. 77·5%, p = 0·006). Reaching low-risk profile of PAH (hazard ratio [HR] 0·34, 95% confidence interval [CI] 0·15-0·79, p = 0·012) and reaching lupus low-disease-activity state (HR 0·33, 95% CI 0·14-0·82, p = 0·016) were independent predictors of survival. The rate of achieving low-risk profile for PAH was considerably higher in patients initially treated with intensive immunosuppressive and dual-PAH-targeted therapies. Conclusions Over the last decade in China, the clinical characteristics of patients with SLE-PAH have evolved and survival has improved. Early PAH detection and dual treatment-to-target strategies for both PAH and SLE have contributed to this improvement in survival. What is new? This is the largest multi-center prospective cohort study of SLE-PAH with the longest follow-up period describing changes in the characteristics, treatment regimen, and long-term survival of patients with SLE-PAH. Our study showed that the 5-year survival rate of patients with SLE-PAH has increased remarkably from 77·5% to 88·1% during the last decade. Our study demonstrated that reaching lupus low-disease-activity state is independently associated with reduced mortality. Significantly more patients reached low-risk profile of PAH during follow-up with initiation of intensive immunosuppressive therapy. What are the clinical implications? Our study emphasised on the importance of achieving dual treatment goals for both SLE and PAH (dual treat-to-target strategy). Earlier detection of PAH in patients with SLE, timely initiation of intensive immunosuppressive therapy, and upfront combination PAH-targeted therapy benefit patients in achieving PAH low-risk profile.